Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.40 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070705 | 1.00 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070654 | 1.00 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3838209 | 0.89 | IGF1R (0.39) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070602 | 0.89 | IGF1R (0.39) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL241160 | 0.88 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL1986354 | 0.88 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL2368070 | 0.88 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3838782 | 0.87 | PTGER2 (0.39) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL28427156 | 0.85 | PTGER2 (0.41) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL4306374 | 0.85 | PTGER2 (0.41) | IGF1RHMOX1MEN1KMT2ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014142298-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1781101-A2 | NOVEL NUCLEOSIDE DERIVATIVES | Metabasis Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006033709-A2 | NOVEL NUCLEOSIDE DERIVATIVES | METABASIS THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | H1-0, H1-2, HDAC1 | IGF1R 212/4885HMOX1 206/4885MEN1 1824/4885 |
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | IGF1R 1235/4885HMOX1 4137/4885MEN1 2110/4885 |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | IGF1R 2183/4885HMOX1 4023/4885MEN1 3801/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | IGF1R 4745/4885HMOX1 2518/4885MEN1 3629/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | IGF1R 4752/4885HMOX1 3730/4885MEN1 3116/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | IGF1R 4804/4885HMOX1 4112/4885MEN1 3092/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | IGF1R 4752/4885HMOX1 3648/4885MEN1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.